4Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post- menopausal patients with advanced breast cancer: arandomized double- blind, the' nordic' phase Ⅲ study[J].Br J Cancer, 1997, 76( 2): 270.
5Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal wonen: results from the more randomized trial Multip- le Outcomes of Raloxifene Evaluation[J].JAMA, 1999, 16( 23): 2 189.
6Wells SJ, Worgul TJ, Samojlik E, et al. Comparison of surgical adrenalectomy to medical adrenalectomy in pa- tients with metastatic carcinoma of the breast[J].Can- cer Res, 1982, 42( 8 Suppl): 3 454.
7Thurlimann B, Castiglione M, Hsu- Schmitz SF, et al. Formestane versus megestrol acetate in postmenolausal breast cancer patients after failure of tamoxifen: a phase Ⅲ prospective randomized cross over trial of sec- ond line hormonal treatment[J].Eur J Cancer, 1997, 33( 7): 1 017.
8Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first- line therapy for advanced breast cancer in postmenopausal women: resul- ts of a North American multicenter randomized trial[J].J Clin Oncol, 2000, 18( 22): 3 758.
9Dombernowsky P, Smith I, Falkson G, et al. A new or- al aromatase inhibitor for advanced breast cancer: double- blind randomized trial showing a dose effect and improved efficacy and tolerability compared with mege- strol acetate[J].J Clin Oncol, 1998, 16( 2): 453.
10Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first- line the- rapy for postmenopausal women with advanced breast cancer: results of a phase iii study of the international letrozole breast cancer group[J].J Clin Oncol, 2001, 19( 10): 2 596.
二级参考文献20
1[1]Glazier MG,Bowman MA.A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy[J].Arch Intern Med,2001,161(9): 1 161.
2[2]Kass Wolff JH.Bone loss in adolescents using[J].J Soc Pediatr Nurs,2001,6(1): 21.
3[3]Compston JE.Sex steroids and bone[J].Physiol Rev,2001,81(1): 419.
4[4]Adachi JD,Sargeant EJ,Sagle MA,et al.A double- blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy[J].Br J Obstet Gynaecol,1997,104(1): 64.
5[5]Writing Group for the PEPI.Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions(PEPI)trial[J].JAMA,1996,276(17): 1 389.
6[6]Jeffcoate W.Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency[J].Ann Clin Biochem,1999,36(1): 151.
7[7]Futamura Y.Effects of medroxyprogesterone acetate and beta- estradiol on interleuki- 6 production from osteoblasts and bone marrow macrophages of wistar rats of different ages[J].J Toxicol Sci,1995,20(2): 155.
8[8]Cantatore FP,Loverro G,Ingrosso AM,et al.Effect of oestrogen replacement on bone metabolism and cytokin_ es in surgical menopause[J].Clin Rheumatol,1995,14(2): 157.
9[9]MacNamara P,Loughrey HC.Messenger RNA transcripts coding for progesterone receptor A and B isoforms are expressed in human osteoblast cells[J].Bio_ chem Soc Trans,1998,26(1): 1.
10[10]Gunhan M,Gunhan O,Celasun B,et al.Estrogen and progesterone receptors in the peripheral giant cell granulomas of the oral cavity[J].J Oral Sci,1998,40(2): 57.
9Higgins J, Green S.Cochrane Handbook for Systematic Reviews oflnterventions[M].Published by John Wiley-Sons Ltd., 2008, Part2 : Table 8.5.c.
10Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98[J]. Breast Cancer Res Treat, 2007,105( 1 ) : 55.
